HealthDay News – According to a study published online September 8 in the Journal of General Internal Medicine, uptake of monoclonal antibody treatment to COVID-19 is low.
Timothy S. Anderson, MD, of Beth Israel Deaconess Medical Center in Boston, and colleagues examined outpatient medical claims from the Symphony Health medical claims database to identify trends in the use of monoclonal antibody treatments (bamlanivimab, casirivimab / imdevimab, and bamlanivimab / etesevimab) evaluate. for COVID-19 between November 9, 2020 and April 11, 2021.
The researchers found that 69,377 patients received treatment with monoclonal antibodies, while 20 million cases of COVID-19 were diagnosed during the study period. The most common treatment used was bamlanivimab (84.6 percent), followed by casirivimab / imdevimab (12.8 percent) and bamlanivimab / etesevimab (2.6 percent). Characteristics of the patients who received the treatments were younger than 65 years (57.5 percent), female gender (53.8 percent), commercial insurance (62.3 percent) and their location in the south (50.8 percent) . Medicaid recipients made up 10 percent of the database, but only 3.3 percent of those who received monoclonal antibodies. Weekly monoclonal antibody use peaked in the week of January 4, 2021 with 7,243 treatments administered.
“These drugs were approved on the cusp of the biggest surge in COVID-19 hospital admissions and in the early stages of vaccine adoption, so healthcare systems may not have the capacity to open monoclonal antibody clinics immediately,” Anderson said in a statement. “However, we expected their use to continue to grow over time and were surprised that the use of monoclonal antibodies declined sharply in early 2021.”
Summary / full text
COVID19 general medicine